Astellas appoints VP of Scientific and Medical Affairs

pharmafile | November 9, 2012 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Jeffrey Bloss 

Astellas has announced Jeffrey Bloss has joined the company as vice president of its Scientific and Medical Affairs (ASMA) division.

Bloss, a gynecologic oncologist, will report to president and chief executive Masao Yoshida.

“Bloss is joining Astellas at an exciting time, on the heels of two product launches,” Yoshida said. “I believe his proven experience in building a strong Medical Affairs group, excellent leadership and strong collaborative skills will take ASMA and Astellas to the next level as we work to achieve the goals for the Americas.”

Bloss will be responsible for leading the US medical affairs organisation and also support the medical affairs function in Canada and Latin America.

He joins Astellas from GlaxoSmithKline Oncology where he served as vice president and head of global medical affairs. Bloss has more than a decade of experience in the pharma industry, beginning in 2001 when he joined Eli Lilly as a senior clinical research physician. He has also held management positions at Genentech, Onyx Pharmaceuticals and Xenocor.

Related Content

Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager

Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration …

Chemotherapy

EMA accepts Astellas’ MAA for Zolbetuximab

Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the company’s marketing …

shaking-hands-gb7ac17374_1920

Astellas and Cullgen enter into $1.9bn strategic collaboration to progress protein degraders

Japanese pharmaceutical company Astellas and US-based clinical-stage biopharmaceutical company Cullgen have announced that they have …

Latest content